文献速递间质性肺疾病

吸入一氧化氮治疗纤维化及晚期间质性肺病:随机对照试验的系统综述与meta分析

Inhaled nitric oxide in fibrotic and advanced interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials
RSS 订阅 · PubMed 高证据 · 肺动脉高压 · 2026-06-22

该系统综述与meta分析纳入4项RCT共274例间质性肺病患者,比较吸入一氧化氮与安慰剂。结果显示iNO在6分钟步行距离、中高强度体力活动及任何不良事件方面与安慰剂均无显著差异,不支持常规使用iNO。

要点

  • iNO与安慰剂在6分钟步行距离上无显著差异(MD 1.83m;95%CI -12.98至16.64;p=0.81)。
  • iNO与安慰剂在任何不良事件上无显著差异(RR 1.12;95%CI 0.97至1.30;p=0.12)。
  • iNO与安慰剂在中高强度体力活动上无显著差异(SMD 0.32;95%CI -0.93至1.56;p=0.39)。

核心结论

  • 吸入一氧化氮未改善间质性肺病患者的6分钟步行距离或中高强度体力活动。
  • 研究结果不支持在该人群中常规使用吸入一氧化氮。

研究设计与样本

  • 系统综述与meta分析,检索PubMed、Embase、Cochrane数据库及ClinicalTrials.gov的随机对照试验。
  • 共纳入4项RCT(含1项交叉试验),274例间质性肺病患者,其中172例接受iNO。
  • 中位随访期为12周。
  • 主要终点为6分钟步行距离,次要终点为中高强度体力活动,安全终点为任何不良事件。

主要发现

  • iNO与安慰剂在6分钟步行距离上可能无差异(MD 1.83m;95%CI -12.98至16.64;p=0.81)。
  • iNO与安慰剂在任何不良事件上可能无差异(RR 1.12;95%CI 0.97至1.30;p=0.12)。
  • iNO与安慰剂在中高强度体力活动上可能无差异(SMD 0.32;95%CI -0.93至1.56;p=0.39)。

临床怎么用

  • 对于间质性肺病(含纤维化及晚期)患者,不应常规使用吸入一氧化氮改善运动能力。
  • 临床决策应个体化,现有证据不支持将iNO作为该人群的常规治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PLoS One. 2026 Jun 22;21(6):e0351862. doi: 10.1371/journal.pone.0351862. eCollection 2026. ABSTRACT PURPOSE: Interstitial lung disease (ILD) can lead to pulmonary hypertension (PH), contributing to reduced exercise capacity in patients with ILD. Inhaled nitric oxide (iNO) reduces pulmonary artery pressure and pulmonary vascular resistance and may improve exercise capacity in this population; however, the available evidence remains limited. Therefore, we conducted a systematic review and meta-analysis to compare the efficacy and safety of iNO versus placebo in patients with ILD. METHODS: We systematically searched PubMed, Embase, Cochrane databases, and ClinicalTrials.gov for randomized controlled trials (RCTs) comparing iNO with placebo in patients with ILD. The primary endpoint was 6-minute walk distance (6MWD). Secondary endpoint was moderate-to-vigorous physical activity (MVPA). Safety endpoint was any adverse events. Continuous endpoints were reported using mean differences (MDs) or standardized mean differences (SMDs), and binary endpoints were reported using risk ratios (RRs), all with 95% confidence intervals (CIs). RESULTS: Four RCTs, including one crossover trial, enrolling 274 patients were analyzed. Of these, 172 received iNO. The median follow-up period was 12 weeks. In the pooled analyses, iNO likely results in little to no difference in 6MWD compared with placebo (MD 1.83m; 95% CI -12.98 to 16.64; p = 0.81), and may result in little to no difference in any adverse events (RR 1.12; 95% CI 0.97 to 1.30; p = 0.12) and MVPA (SMD 0.32; 95% CI -0.93 to 1.56; p = 0.39). CONCLUSION: INO did not demonstrate improvements in 6MWD or MVPA. These findings do not support routine use of iNO in this population. PMID: 42329957 | PMC: PMC13286226 | DOI: 10.1371/journal.pone.0351862

来源:PubMed 高证据 · 肺动脉高压,查看原文。版权归原作者所有。

引用

  1. PubMed 高证据 · 肺动脉高压:Inhaled nitric oxide in fibrotic and advanced interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。